MedTrace Logo

A Study of TAS3731 in Healthy Adults

NCT05691660 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 238

Last updated 2024-08-14

No results posted yet for this study

Summary

To evaluate the safety of single and repeated administration of TAS3731.

Conditions

  • Healthy Adult Males

Interventions

DRUG

TAS3731 Dose1

Oral administration,1 day,QD

DRUG

TAS3731 Dose2

Oral administration,7 days,QD

DRUG

TAS3731 Dose3

Oral administration,7 days,BID

DRUG

Placebo

Oral administration, 1 day,QD

DRUG

Placebo

Oral administration, 7 days,QD

DRUG

Placebo

Oral administration, 7 days,BID

Sponsors & Collaborators

  • Taiho Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Taiho Pharmaceutical Co., Ltd. · Taiho Pharmaceutical Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
39 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-01-17
Primary Completion
2024-05-21
Completion
2024-05-21

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05691660 on ClinicalTrials.gov